Navigation Links
Unique New Initiative by World-Recognized Specialists in Heart Disease and Diabetes to Reduce Residual Vascular Risk Launched Today
Date:11/9/2008

NEW ORLEANS and LOS ANGELES, November 10 /PRNewswire/ --

- Current Treatment Fails to Abolish Majority of Vascular Risk

- Residual Risk Reduction Initiative (R3i) Calls for Action to Reduce the Lipid-Related Residual Vascular Risk Unaddressed by Current Standards of Care in Millions of Patients With Heart Disease and Diabetes

Internationally recognized specialists from North America, Europe, Asia and Japan have come together today to launch the Residual Risk Reduction initiative (R3i) - a unique global program to evaluate and reduce the excess risk of myocardial infarction, stroke, kidney disease, loss of vision and non-traumatic limb amputation which exists in many patients with heart disease and diabetes despite optimal, currently available care.

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and microvascular complications in patients with atherogenic dyslipidemia, characterized by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care. This lipid abnormality is typical in patients with type 2 diabetes or metabolic syndrome and common in patients with established cardiovascular disease.

The President of the R3i, Professor Jean-Charles Fruchart of the University of Lille, France said: "We now have unequivocal evidence from numerous studies showing that greater reductions in low-density lipoprotein cholesterol, blood pressure and blood sugar alone will have little, if any, additional impact on residual vascular risk. Therefore, we urgently need new strategies to address other modifiable risk factors such as atherogenic dyslipidemia, a strong contributor to residual vascular risk in millions of patients with diabetes and cardiovascular disease."

The R3i will address this major public health problem. In its manifesto published today in Diabetes & Vascular
'/>"/>

SOURCE Residual Risk Reduction Initiative (R3i)
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Nanoscience Instruments, Inc. Announces Distribution of Nascatec's Complete Line of Unique AFM Probes and Sensors
2. Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service
3. Bruker Introduces HyperQuant™, a Unique Bench-Top NMR Reader to Quantify Hyperpolarization
4. SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles
5. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
6. SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles
7. BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use
8. Applied Isotope Technologies will Exclusively Supply Biochemimarker(TM) Discovery Products for a Unique Pilot Study on Autism
9. Biotherm Announces a Unique Dermobiotic Three-Step Anti-Cellulite Slimming Treatment
10. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
11. Unique infrared technique finds applications in nanoscience
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2009)... Johnson & Johnson today announced that Ax...olecular Biology at the Max Planck Institute of Bi...to novel cancer therapies including Herceptin(R) (...Janssen Award for Biomedical Research. An independ...d Dr. Ullrich, who on September 8 will receive a $...
(Date:7/1/2009)... to establish duration of efficacy from two hours ... ADHD , , HOLLYWOOD, Fla., July 1 /PRNewswire-F...), the global specialty biopharmaceutical company,...t found VYVANSE(R) (lisdexamfetamine dimesylate) C...fter administration during a simulated workplace e...
(Date:7/1/2009)...irstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ) ann...unds of over $4 million from institutional and pri... million private placement from three Asia-based i... investment obtained by NeoStem in the past two an...ffiliates of Suzhou Erye Pharmaceuticals Company, ...
(Date:7/1/2009)...1 Gerresheimer AG, a,le... for the pharma & life,science industry, has ...not,part of the MDAX company,s core business, to ...ale of the Technical Plastics segment Gerresheimer...ep in its focus on the core,business of pharma &a...
Breaking Biology Technology:Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 2Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 3Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 4Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 5Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 2Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 3Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 4Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 5Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 6Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 7Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 8NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State 2NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State 3Gerresheimer Sells Technical Plastics Business 2
...n Bay, Wis. - The Green Bay Fire Department has...002 as a database to keep and manage its records. ...e department recently awarded BIO-key Internation...f , an automatic scheduling system from Principal...ogram seemed a natural choice for the department. ...
...son, Wis. - The Proceedings of the National Acad...rs at the University of Wisconsin-Madison and Co... of the genetic disorder Huntington,s disease. , ,...dison molecular geneticist Jerry Yin and UW-Madiso...vating levels of the proteins CREB and HSP-70 in ...
...son, Wis. - When Hurricane Dennis reached landfal... too surprising a development. Weather Central In... solutions had already forecast almost the exact l...ather Central,s Super MicroCast forecast model, a ...throughout the country, showed Hurricane Dennis ma...
...son, Wis. - R&D Magazine has selected Bruker A... Award, which recognizes the most technologically ...ce during the past year. , ,The VANTEC-2000 system...logy useful in the life science, materials science...ers to determine small molecule and protein struct...
Other Biology Technology:IT application streamlines fire fighting 2IT application streamlines fire fighting 3
(Date:7/2/2009)... pathology and laboratory medicine at The Universi...received a Career Development Award from the Natio...port Smith,s research into the development of a th...order, whose immune systems are resistant to treat...0 males born in the United States. , Through the...
(Date:7/2/2009)...es its birth on the 4th of July, University of Mia...n coral reef nursery scientists will be celebratin...dministration (NOAA) today announced that The Natu...orn coral recovery project, including Lirman,s nur...rt from the American Recovery and Reinvestment Act...
(Date:7/1/2009)...y announced that Axel Ullrich, Ph.D., director of ...nck Institute of Biochemistry in Germany, whose di...ding Herceptin (trastuzumab) , is the winner of th...rch. An independent committee of world-renowned s... will receive a $100,000 prize during a ceremony i...
(Date:7/1/2009)... centromere, a key cellular structure in powering ...e cell division, has just earned him a paper in N...ation grant, of 50,000 euro per year, for a maximu...rnia to the Instituto Gulbenkian de Cincia (IGC), ...anisms group. The Nature Cell Biology paper, pub...
Breaking Biology News(10 mins):UT scientist receives hemophilia research award 2Nursery programs for corals receive TLC from NOAA this Independence Day 2Axel Ullrich named winner of 2009 Dr. Paul Janssen Award for Biomedical Research 2Double success for Instituto Gulbenkian de Ciencia scientists working on chromosome segregation 2Controversies in science and technology explored in new book from Mary Ann Liebert 12286 1Controversies in science and technology explored in new book from Mary Ann Liebert 12286 2XTENT Announces 2007 Financial Results 12282 1XTENT Announces 2007 Financial Results 12282 2XTENT Announces 2007 Financial Results 12282 3XTENT Announces 2007 Financial Results 12282 4XTENT Announces 2007 Financial Results 12282 5XTENT Announces 2007 Financial Results 12282 6No Difference Found in Treatments for Acute Kidney Failure 12280 1No Difference Found in Treatments for Acute Kidney Failure 12280 2No Difference Found in Treatments for Acute Kidney Failure 12280 3Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark 12276 1Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark 12276 2Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark 12276 3
...rvard University and University College London hav...socially disabling inability to recognize or disti...d a related web site ( www.faceblind.org ) to iden...e than scientists had identified previously. , Th...sell at Harvard and Bradley Duchaine at University...
...sed data from scans of 183 subjects to identify br...iety of cognitive tasks, such as reading, learning...n action can be compared to a symphony, with speci...time to produce the desired melody, then the regio...conductors, researchers at Washington University S...
...ious diseases run in families because one inherits...rally agree that an individual,s genetic makeup co...ctious disease, new findings from researchers in F... in a single gene is enough to dramatically alter ...ns. , Howard Hughes Medical Institute (HHMI) in...
...do not haphazardly flail about looking for a host ...nts and identify potential hosts by their emission...ogists. , "We are interested in how plants respond...sect interactions," says Dr. Consuelo M. De Moraes...rising to see how little was available on how abov...
Other Biology News:Tests for 'face-blindness' reveal disorder may not be so rare 2Master planners in brain may coordinate other areas' roles in cognitive tasks 2Master planners in brain may coordinate other areas' roles in cognitive tasks 3Inheriting a tendency to brain infection 2Inheriting a tendency to brain infection 3Parasitic plants sniff out hosts 2Parasitic plants sniff out hosts 3
TUNEL Apoptosis Detection Kit
The NOS assay kit measures NOS activity by monitoring the conversion of radiolabeled arginine to citrulline. This assay is simple, sensitive, and specific for NOS activity and can be used with both c
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems.
Mouse Axl MAb (Clone 175128)
Biology Products: